A Phase 2 interventional study of AVP-786 and Placebo in Disinhibition Syndrome, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.
Eligible participants for this study must have a diagnosis of Neurodegenerative Disorder and must exhibit disinhibition syndrome of sufficient severity to warrant treatment.
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study consisting of two 6-week treatment periods.
Approximately 12 participants will be enrolled at approximately 2 centers in the United States.
Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo drug to be taken twice a day for 6 weeks
Drug: Placebo
Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
Drug: AVP-786
Drug pages: Deudextromethorphan · Quinidine
d6-DM/Q
Also known as: Deuterated (d6)-dextromethorphan (DM)/Quinidine (Q)
matching placebo
Change From Baseline in the Disinhibition Domain of the Neuropsychiatric Inventory (NPI)
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Total NPI Score
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the NPI Total Caregiver Distress
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the NPI Disinhibition Domain Caregiver Distress
Time frame: Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14
Change From Baseline for the Frontal Behavioral Inventory (FBI) Total Score
Time frame: Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14
Change From Baseline for the FBI Disinhibition Domain Score
Time frame: Baseline; Week 1, Week 3, Week 6, Week 9, Week 11, and Week 14
Change From the First Assessment for the Modified Clinical Global Impression of Change (mCGIC) Scale
Time frame: Week 3, Week 6, Week 11, and Week 14
Change From the First Assessment for the Patient Global Impression of Change (PGIC) Scale
Time frame: Week 3, Week 6, Week 11, and Week 14
Change From Baseline for the Quality of Relationships (QoR) Scale
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Quality of Life (QoL) Scale
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Interpersonal Reactivity Index (IRI)
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Center for Neurologic Study-Lability Scale (CNS-LS)
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Mini-Mental State Examination (MMSE)
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Cornell Scale for Depression in Dementia (CSDD)
Time frame: Baseline; Week 6, Week 8, and Week 14
Change From Baseline for the Stroop Color and Word Task
Time frame: Baseline; Week 6, Week 8, and Week 14
| Milestone | AVP-786; Placebo | Placebo; AVP-786 |
|---|---|---|
| Started | 1 | 0 |
| Completed | 1 | 0 |
| Not completed | 0 | 0 |
| Milestone | AVP-786; Placebo | Placebo; AVP-786 |
|---|---|---|
| Started | 1 | 0 |
| Completed | 1 | 0 |
| Not completed | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over up to 22 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| AVP-786 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Placebo | AVP-786 |
|---|---|---|
| Blood bilirubin increasedInvestigations | 0/1 | 1/1 |
| Blood creatine phosphokinase increasedInvestigations | 0/1 | 1/1 |
A limited number of participants were enrolled prior to study termination.
| Age, Categorical(Participants) | AVP-786; Placebo | Placebo; AVP-786 | Total |
|---|---|---|---|
| <=18 years | 0 | — | 0 |
| Between 18 and 65 years | 0 | — | 0 |
| >=65 years | 1 | — | 1 |
| Sex: Female, Male(Participants) | AVP-786; Placebo | Placebo; AVP-786 | Total |
|---|---|---|---|
| Female | NA | — | NA |
| Male | NA | — | NA |
| Race (NIH/OMB)(Participants) | AVP-786; Placebo | Placebo; AVP-786 | Total |
|---|---|---|---|
| American Indian or Alaska Native | NA | — | NA |
| Asian | NA | — | NA |
| Native Hawaiian or Other Pacific Islander | NA | — | NA |
| Black or African American | NA | — | NA |
| White | NA | — | NA |
| More than one race | NA | — | NA |
| Unknown or Not Reported | NA | — | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Oct 2017, 22 months.
Results were first posted in Oct 2020, 3 years after primary completion. A results delay was requested in Oct 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Otsuka Pharmaceutical Development & Commercialization, Inc. →